Shandong Sinobioway Biomedicine Co., Ltd. / Fundamentals
Income statement
- Net revenue
€36.92M - Cost of goods sold
€7.53M - Gross profit
€29.39M - SG&A expenses
€35.15M - R&D expenses
€2.86M - EBITDA
-€12.13M - D&A
€19.25K - EBIT
-€15.94M - Interest expenses
€0.00 - EBT
-€20.20M - Tax expenses
-€495.02K - Net income
-€17.43M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€3.62M - Changes in working capital
-€366.71K - Operating cash flow
-€4.22M - Capex
€1.79M - Other investing cash flow
-€15.48M - Net investing cash flow
€8.34M - Total cash dividends paid
-€9.99K - Issuance of common stock
€0.00 - Debt repayment
-€748.26K - Other financing cash flow
-€179.11K - Net financing cash flow
-€937.37K - Foreign exchange effects
-€11.56 - Net change in cash
€27.07M - Cash at end of period
€52.68M - Free cash flow
-€2.42M
Balance sheet
- Cash and cash equivalents
€52.95M - Cash and short-term investments
€52.95M - Total receivables
€21.07M - Inventory
€10.44M - Other current assets
€2.38M - Total current assets
€86.84M - Property, plant & equipment
€32.45M - Goodwill
€0.00 - Intangible assets
€10.90M - Long-term investments
€0.00 - Other non-current assets
€126.21M - Total non-current assets
€171.09M - Total assets
€257.94M - Accounts payable
€3.08M - Short-term debt
€273.43K - Other current liabilities
€7.27M - Total current liabilities
€10.83M - Long-term debt
€477.02K - Deferred tax liabilities
€1.24M - Other non-current liabilities
€9.49M - Total non-current liabilities
€11.86M - Total liabilities
€22.69M - Common stock
€27.26M - Retained earnings
€75.99M - Other equity
€0.00 - Total equity
€235.25M - Total liabilities and shareholders' equity
€257.94M
Company information
- Market capitalization
€701.76M - Employees
476 - Enterprise Value
€5.74B
Company ratios
- Gross margin
-
79.6% Much better than peer group: 24.7% - EBITDA margin
-
-32.9% Much worse than peer group: 16.8% - EBIT margin
-
-43.2% Much worse than peer group: 8.0% - EBT margin
-
-54.7% Much worse than peer group: 9.1% - Net margin
-
-47.2% Much worse than peer group: 6.8% - ROE
-
-7.4% Worse than peer group: 4.7% - ROA
-
-6.8% Worse than peer group: 3.1% - Asset turnover
-
14.3% Much worse than peer group: 67.5% - FCF margin
-
-16.3% Worse than peer group: -2.2% - FCF yield
-0.9% - Efficiency ratio
132.9% - Net sales per employee
-
€77.57K - Net income per employee
-
-€36.61K